P
arenteral medication therapy may account for a significant portion of patient costs during hospital admission. 1 Many medications have pharmacokinetic profiles that make them suitable for conversion from i.v. to oral administration, with high bioavailability and predictable absorption. 2 Patients are frequently initiated on i.v. medications during an acute illness. However, despite availability of suitable oral dosage forms, many patients remain on i.v. medications after they are able to take oral doses. Appropriate conversion of i.v. to oral medications, especially for antimicrobials, can reduce hospital costs by decreasing drug acquisition costs and shortening length of stay. [3] [4] [5] Other positive outcomes of conversion include a decreased risk of i.v. line infection or thrombosis, decreased nursing requirements, and increased patient comfort and safety after removal of i.v. lines. [6] [7] [8] [9] [10] Pharmacists play an important role in stewardship efforts within an institution. In a statement specifically regarding antimicrobial stewardship, ASHP commented that "pharmacists have a responsibility to take prominent roles in . . . stewardPurpose. Results of a study to implement targeted interventions to increase the number of documented i.v.-to-oral conversions and to increase cost savings from these documented conversions are reported. Methods. A before-and-after analysis of i.v.-to-oral conversions at an academic medical center following the addition of targeted interventions to an existing pharmacistinitiated conversion program was conducted. Targeted interventions included staff training on i.v.-to-oral conversions, implementation of a new documentation system, and feedback to the staff. Major outcomes studied included the total number of i.v.-to-oral conversions documented per month and the cost savings generated by these conversions.
Results. The mean ± S.D. number of i.v.-tooral conversions documented per month significantly increased after the implementation of targeted interventions (25 ± 9 before and 57 ± 6 after implementation, p < 0.0001). There was a nonsignificant increase in cost savings generated per month after implementation of the interventions. The most commonly converted medication was pantoprazole. Conversions of levetiracetam generated the highest cost savings. Conclusion. Addition of several targeted interventions to an existing pharmacistinitiated i.v.-to-oral conversion program led to a significant increase in the total number of documented conversions. Am J Health-Syst Pharm. 2015; 72(suppl 3):S145-9 ship programs."
11 Pharmacist-driven stewardship programs that have included efforts to convert i.v. to oral medications have increased the rate of conversions and decreased inappropriate i.v. medication usage. 3, 4, 8 Additionally, improvements in information technology have allowed for more efficient identification of patients for whom conversion might be suitable. 12 At Brigham and Women's Hospital (BWH), a policy allows pharmacists to initiate the conversion of medications from i.v. to oral under the supervision of a physician when certain clinical criteria are met. However, electronic documentation of these conversions had historically been relatively low, averaging less than one conversion per day. We sought to determine whether the implementation of targeted interventions would increase the documented number of conversions and the associated cost savings.
Background
Conversion policy. BWH is a 793-bed academic medical center providing acute, tertiary care for adult patients with general medical, cardiothoracic, orthopedic, hematologic, oncological, neurologic, obstetric and gynecological, neonatal, urologic, pulmonary, and gastrointestinal conditions. The conversion policy was approved by the institutional pharmacy and therapeutics committee in December 2004. Pharmacists, with a cosignature from the providing prescriber, can write orders to discontinue the candidate i.v. medication and place new orders for an equivalent oral medication when clinical criteria are met. First, the patient must be tolerating oral medications or an oral diet. Second, the patient must not have a condition that may produce unreliable oral absorption, such as gastrointestinal obstruction or a gastrointestinal motility disorder. Finally, the patient must not be receiving vasopressors.
Pharmacy clinical surveillance system. The conversion policy is supported at BWH by a pharmacy clinical surveillance system (PCSS) that uses novel computerized technology to help pharmacists monitor patients in real time. 13 Data from several separate clinical systems are aggregated and analyzed to provide clinicians with rules-based alerts (RBAs) for their patients. The PCSS also enables clinicians to document their clinical interventions and allows for reporting of intervention statistics.
One active RBA at BWH is a medication alert for possible conversion of an i.v. to an oral medication. An RBA is generated when a patient has an active order for a candidate i.v. medication and an active order for an oral medication. The candidate i.v. medications are acyclovir, azithromycin, chlorothiazide, ciprofloxacin, clindamycin, doxycycline, fluconazole, levetiracetam, levofloxacin, linezolid, metronidazole, moxifloxacin, mycophenolate mofetil, pantoprazole, posaconazole, tedizolid, trimethoprim-sulfamethoxazole, and voriconazole.
This RBA does not apply if (1) there are future or active orders for an oral medication in the same class as the candidate i.v. medication, (2) the candidate i.v. medication has a future start date, (3) the patient has, in the last 14 days, had a specimen of cerebral spinal fluid collected for culturing, or (4) the order for the candidate i.v. medication or the oral medication is for a one-time dose. The RBA is retracted by the PCSS when the candidate i.v. medication is discontinued or placed on hold, the patient is no longer taking any oral medications, or a future oral medication in the same class as the candidate i.v. medication is ordered.
The department of pharmacy services has 80 full-time pharmacists, consisting of staff pharmacists and pharmacy residents, who use the PCSS in fulfilling their daily responsibilities. BWH has implemented an integrated practice model in which all pharmacists are involved in direct patient care. As a result, use of the PCSS is encouraged among all pharmacists, not just clinical pharmacy specialists. Night-shift pharmacists use the PCSS but deal with a limited number of active RBAs; the RBA for conversion of i.v. to oral medications is not typically acted on during the night shift.
Methods
We conducted a before-and-after analysis of i.v.-to-oral conversions documented at BWH following the implementation of a series of targeted interventions. The preintervention period ran from January through August 2014, and the postintervention period ran from October 2014 through January 2015. September 2014 was considered a washout period during which targeted interventions were implemented within the department. BWH's institutional review board determined that its approval of the study was not required because the interventions were deemed a quality-improvement initiative and patient care was not directly affected by our analysis.
Targeted interventions included staff education on i.v.-to-oral conversions, improvements in intervention documentation within the PCSS, and provision of feedback to the staff. Staff education was pro-vided during a 20-minute inservice meeting for pharmacists held during the change from the day to the evening shift. Topics included the importance of i.v.-to-oral conversions, outcomes positively affected by conversions, and pharmacists' role in the conversions. The conversion policy was emphasized, and the patient-specific clinical criteria were reviewed. Finally, medications with the largest differences in acquisition cost between i.v. and oral forms were highlighted.
Within the PCSS, changes were made to the intervention documentation system to increase pharmacist efficiency. A separate intervention that could be documented within the PCSS was developed for each candidate i.v. medication. By providing pharmacists with a unique option for each medication, a free-text explanation of their intervention was no longer required. Additionally, the location of the i.v.-to-oral intervention tab was optimized within the PCSS to improve efficiency.
Finally, feedback was provided to staff at least monthly in announcements at daily staff meetings, during pharmacist inservice meetings, and via e-mail communication. The total number of documented i.v.-to-oral conversions was reported, along with future goals for such conversions. Additional points of emphasis included conversion of medications with a high cost difference between i.v. and oral forms and appropriate timing of conversions.
Outcomes. The primary outcomes were the total number of i.v.-to-oral conversions documented via the PCSS per month and the cost savings generated by these conversions. Each conversion was adjudicated by a study investigator using the institution's electronic medication administration record. The cost savings generated by each conversion was calculated by multiplying the number of oral doses administered after conversion by the difference between injectable and oral drug acquisition costs per dose. 14 It was assumed that all doses of the candidate medication would have been given intravenously had they not been converted to oral form by the pharmacist. 15 Calculations regarding cost savings were made from the perspective of the pharmacy department and represented drug acquisition costs. All drug acquisition cost data were taken from a single time point in September 2014.
Additional outcomes evaluated included the total number of i.v.-tooral RBAs generated per month, the i.v. medications that were converted, the percentage of eligible medications that were converted, and where and when the conversions occurred. Possible locations were an intensive care unit (ICU), a hematologyoncology unit, a general medicalsurgical unit, and a peripartum unit. Conversions were grouped by shift: day (7 a.m. to 3 p.m.), evening (3 p.m. to 11 p.m.), and night (11 p.m. to 7 a.m.).
Statistical analysis. Continuous variables were presented as means ± S.D. or as medians with the interquartile range. Binary variables were presented as numbers and proportions. Student's t test was used to compare continuous outcomes with normal distribution between the preintervention and postintervention periods. The Mann-Whitney U test was used to compare continuous outcomes with nonnormal distributions. The chi-square test was used to compare ratios between the preintervention and postintervention periods.
On the basis of historical data collected at BWH, we expected there to be a mean of 25 conversions documented per month. We calculated that a sample of four preintervention and four postintervention months would be needed to detect a 25% increase in the number of documented conversions per month. 16 The power of the study was set at 80%, with a two-sided alpha error of 5%. The a priori level of significance was 0.05.
Results
Conversions. There was no significant difference in the mean number of i.v.-to-oral RBAs generated per month by the PCSS between the preintervention and postintervention periods, but the number of adjudicated documented conversions more than doubled (p < 0.0001) between the two periods ( Table 1 ). The most commonly converted medication in both study periods was pantoprazole. Other commonly converted medications included metronidazole, levofloxacin, and levetiracetam.
Conversions occurred most frequently on general medical-surgical units; the location of conversions did not differ significantly between study periods; about one fourth of documented conversions occurred in an ICU during both periods. Conversions occurred most frequently during the day shift during both periods.
Cost savings. There was not a significant difference between study periods in the mean cost savings per month or in the mean cost savings per conversion (Table 2) . Conversions of levetiracetam generated the highest percentage of overall cost savings during both periods and the highest cost savings per conversion (preintervention, $293.30; postintervention, $293.46).
Discussion
Despite the presence of a policy that allows for pharmacist-initiated i.v.-to-oral conversion, documentation of conversions was initially low. Enhanced efficiency of documentation and continual staff education led to a higher number of documented conversions. Our analysis describes the implementation of a series of potentially reproducible interventions that significantly increased the number of documented conversions.
Reasons why documentation of conversions was low at BWH are unclear but may have included lack of awareness of the conversions' importance and of why they needed to be documented, lack of awareness of the conversion policy itself, and perceived difficulties with and increased time needed for documenting conversions in the PCSS.
Our interventions were designed specifically to target these possible reasons. Staff education provided guidance on the importance of the conversions and the role of the pharmacist in initiating them. Improvements were made to the interventiondocumentation process to make it more efficient and less disruptive of pharmacists' usual workflow. Finally, providing staff members with feedback on their conversion performance kept them focused on carrying out the conversions and on meeting monthly goals. These interventions successfully addressed staff concerns and led to a significant increase in documented conversions.
An argument could be made that our interventions increased documentation of conversions without actually leading to an increased number of completed conversions, but this possibility would probably not account for the large observed increase in documented conversions.
Previous analyses have demonstrated a 10-25% increase in i.v.-to-oral conversions with the implementation of a conversion program. 12, 16 We used the upper limit of that range (25%) in our sample-size calculation and demonstrated an increase in documented conversions of greater than 100%.
There is benefit to increasing documentation of interventions. Reporting metrics of the PCSS are viewed by BWH departmental and institutional leadership. Improving the documentation of interventions, particularly those that correlate with cost savings, helps represent the work 3 implemented a pharmacist-initiated conversion of levofloxacin and observed a significantly shorter hospital length of stay and decreased overall healthcare costs. Yen et al. 8 introduced a similar pharmacist-managed antibiotic i.v.-to-oral program and reported significant decreases in i.v. antibiotic usage, inpatient expenditures, and overall length of stay (27 days before the program and 16 days afterward).
Longer duration of central and peripheral venous catheter placement has been demonstrated to significantly increase the risk of lineassociated infection 9 and thrombosis. 10 Conversion to oral medication forms may result in the removal of i.v. lines and theoretically could prevent such complications. Given the design of our study and reliance on electronic surveillance, clinical outcomes for patients involved in our analysis were not obtained.
Despite the presence of a policy allowing for pharmacist-initiated conversion, documentation of conversions at our institution was initially low. Overall, the introduction of a series of potentially replicable interventions led to a significant increase in documented conversions but not to a significant savings in drug acquisition costs. Further research can be conducted to determine the impact of our interventions on clinical outcomes, including hospital length of stay and development of i.v. line infection or thrombosis.
Conclusion
Addition of several targeted interventions to an existing pharmacistinitiated i.v.-to-oral conversion program led to a significant increase in the total number of documented conversions.
